Late-stage trial of Pfizer's Inspra meets primary goal ahead of schedule

Pfizer reported Thursday that it plans to stop enrolling patients ahead of schedule in a late-stage trial of Inspra (eplerenone) after those taking the drug experienced a significant reduction in risk of cardiovascular death or heart failure hospitalisation compared with those receiving placebo. The decision follows an interim analysis by the study's data safety monitoring committee, which found that the EMPHASIS-HF trial had reached its primary efficacy endpoint early. Faiez Zannad, who was part of the study's steering committee, commented: "The…trial had an estimated end date around October 2011 so to have met the pre-defined efficacy endpoints early is certainly a positive outcome."

To read more Top Story articles, click here.